Minami T, Nakagawa H, Yoshimoto S, Asano I, Okazaki Y
Faculty of Pharmaceutical Sciences, Kinki University, Osaka, Japan.
Biol Pharm Bull. 1993 Nov;16(11):1108-10. doi: 10.1248/bpb.16.1108.
Pancreatic metallothionein (MT) and zinc levels were measured after the administration of 4-aminopyrazolo(3,4-d)pyrimidine (4APP) to mice to determine the role of pancreatic MT. 4APP was found to increase the pancreatic MT level dose-dependently; the pancreatic MT level in mice administered 175 mg/kg of 4APP was 3.9 fold higher than that in control mice. When 40 mg/kg or less of 4APP was administered, the zinc concentration of the pancreatic cytosol fraction did not differ from that in control mice, while after 175 mg/kg of 4APP it was 1.7-fold higher. There was no difference in plasma glucose and insulin levels between the controls and mice administered 175 mg/kg of 4APP, although the plasma alpha-amylase activity was reduced in the latter. Moreover, a linear negative relationship was observed between pancreatic MT level and plasma alpha-amylase activity (r = -0.795, p < 0.01). These findings suggest that pancreatic MT is affected by the disruption of the exocrine function in 4APP-administered mouse pancreas.
给小鼠注射4-氨基吡唑并(3,4 - d)嘧啶(4APP)后，检测胰腺金属硫蛋白(MT)和锌水平，以确定胰腺MT的作用。发现4APP能剂量依赖性地提高胰腺MT水平；给予175 mg/kg 4APP的小鼠胰腺MT水平比对照小鼠高3.9倍。当给予40 mg/kg或更低剂量的4APP时，胰腺胞质溶胶部分的锌浓度与对照小鼠无差异，而给予175 mg/kg 4APP后，其锌浓度高1.7倍。给予175 mg/kg 4APP的小鼠与对照小鼠的血糖和胰岛素水平无差异，尽管后者的血浆α-淀粉酶活性降低。此外，观察到胰腺MT水平与血浆α-淀粉酶活性之间呈线性负相关(r = -0.795，p < 0.01)。这些发现表明，在给予4APP的小鼠胰腺中，胰腺MT受外分泌功能破坏的影响。
